Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.

ABSTRACT:

Aims

Dalcetrapib, which targets cholesteryl ester transfer protein activity, is in development for prevention of cardiovascular events. Because dalcetrapib will likely be prescribed with other lipid-modifying therapies such as ezetimibe, a study was performed to investigate potential pharmacokinetic interactions between dalcetrapib and ezetimibe. Lipids changes and tolerability were secondary endpoints.

Methods

Co-administration of dalcetrapib 900 mg (higher than the phase III dose) with ezetimibe was investigated in a three period, three treatment crossover study in healthy males: 7 days of dalcetrapib, 7 days of dalcetrapib plus ezetimibe, 7 days of ezetimibe alone. A full pharmacokinetic profile was performed on day 7 of each treatment.

Results

Co-administration of

SUBMITTER: Derks M 

PROVIDER: S-EPMC3014066 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature